publication . Article . 2016

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies

Hanni Uusi-Kerttula; James Davies; Lynda Coughlan; Sarah Hulin-Curtis; Rachel Jones; Louise Hanna; John D. Chester; Alan L. Parker;
Open Access English
  • Published: 01 Apr 2016 Journal: Oncotarget, volume 7, issue 19, pages 27,926-27,937 (eissn: 1949-2553, Copyright policy)
  • Publisher: Impact Journals LLC
  • Country: United Kingdom
Abstract
// Hanni Uusi-Kerttula 1 , James Davies 1 , Lynda Coughlan 2 , Sarah Hulin-Curtis 1 , Rachel Jones 3 , Louise Hanna 3 , John D. Chester 1, 3 , Alan L. Parker 1 1 Department of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK 2 Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK 3 Velindre Cancer Centre, Cardiff CF14 2TL, UK Correspondence to: Alan L. Parker, e-mail: parkeral@cardiff.ac.uk Keywords: adenovirus, re-targeting, neutralizing antibody, ovarian cancer, αvβ6 integrin Received: February 05, 2016      Accepted: March 28, 2016      Published: April 1, 2016 ABSTRACT Encouraging res...
Subjects
Medical Subject Headings: viruses
free text keywords: Research Paper, adenovirus, re-targeting, neutralizing antibody, ovarian cancer, αvβ6 integrin, R1, Oncology, Virology, biology.protein, biology, Immunology, Virotherapy, medicine.disease, medicine, Pseudotyping, Oncolytic virus, Transduction (genetics), business.industry, business, Cancer cell, Cancer research, Cancer
Related Organizations
67 references, page 1 of 5

Ovarian cancer statistics. Cancer Research UK. 2012

Coughlan, L, Alba, R, Parker, AL, Bradshaw, AC, McNeish, IA, Nicklin, SA, Baker, AH. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses. 2010; 2: 2290-2355 [OpenAIRE] [PubMed]

Xia, D, Henry, LJ, Gerard, RD, Deisenhofer, J. Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1. 7 å resolution. Structure. 1994; 2: 1259-1270 [PubMed]

Zubieta, C, Schoehn, G, Chroboczek, J, Cusack, S. The structure of the human adenovirus 2 penton. Mol Cell. 2005; 17: 121-135 [OpenAIRE] [PubMed]

Wickham, TJ, Mathias, P, Cheresh, DA, Nemerow, GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993; 73: 309-319 [OpenAIRE] [PubMed]

Nicol, CG, Graham, D, Miller, WH, White, SJ, Smith, TAG, Nicklin, SA, Stevenson, SC, Baker, AH. Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther. 2004; 10: 344-354 [PubMed]

Carlisle, RC, Di, Y, Cerny, AM, Sonnen, AFP, Sim, RB, Green, NK, Subr, V, Ulbrich, K, Gilbert, RJC, Fisher, KD, Finberg, RW, Seymour, LW. Human erythrocytes bind and inactivate type 5 adenovirus by presenting coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009; 113: 1909-1918 [OpenAIRE] [PubMed]

Seiradake, E, Henaff, D, Wodrich, H, Billet, O, Perreau, M, Hippert, C, Mennechet, F, Schoehn, G, Lortat-Jacob, H, Dreja, H, Ibanes, S, Kalatzis, V, Wang, JP, Finberg, RW, Cusack, S, Kremer, EJ. The cell adhesion molecule “CAR” And sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Path. 2009; 5: e1000277 [OpenAIRE]

Li, Y, Pong, RC, Bergelson, JM, Hall, MC, Sagalowsky, AI, Tseng, CP, Wang, Z, Hsieh, JT. Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res. 1999; 59: 325-330 [OpenAIRE] [PubMed]

Kim, M, Zinn, KR, Barnett, BG, Sumerel, LA, Krasnykh, V, Curiel, DT, Douglas, JT. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer. 2002; 38: 1917-1926 [OpenAIRE] [PubMed]

Mast, TC, Kierstead, L, Gupta, SB, Nikas, AA, Kallas, EG, Novitsky, V, Mbewe, B, Pitisuttithum, P, Schechter, M, Vardas, E, Wolfe, ND, Aste-Amezaga, M, Casimiro, DR, Coplan, P, Straus, WL, Shiver, JW. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high ad5 titers and implications for potential hiv vaccine trials. Vaccine. 2010; 28: 950-957 [PubMed]

Abbink, P, Lemckert, AAC, Ewald, BA, Lynch, DM, Denholtz, M, Smits, S, Holterman, L, Damen, I, Vogels, R, Thorner, AR, Brien, KL, Carville, A, Mansfield, KG, Goudsmit, J, Havenga, MJE, Barouch, DH. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007; 81: 4654-4663 [OpenAIRE] [PubMed]

Barouch, DH, Kik, SV, Weverling, GJ, Dilan, R, King, SL, Maxfield, LF, Clark, S, Ng'ang'a, D, Brandariz, KL, Abbink, P, Sinangil, F, de Bruyn, G, Gray, GE, Roux, S, Bekker, LG, Dilraj, A, Kibuuka, H, Robb, ML, Michael, NL, Anzala, O, Amornkul, PN, Gilmour, J, Hural, J, Buchbinder, SP, Seaman, MS, Dolin, R, Baden, LR, Carville, A, Mansfield, KG, Pau, MG, Goudsmit, J. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011; 29: 5203-5209 [OpenAIRE] [PubMed]

Kanerva, A, Zinn, KR, Chaudhuri, TR, Lam, JT, Suzuki, K, Uil, TG, Hakkarainen, T, Bauerschmitz, GJ, Wang, M, Liu, B, Cao, Z, Alvarez, RD, Curiel, DT, Hemminki, A. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther. 2003; 8: 449-458 [PubMed]

Morrison, J, Briggs, SS, Green, NK, Thoma, C, Fisher, KD, Kehoe, S, Seymour, LW. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum Gene Ther. 2009; 20: 239-251 [PubMed]

67 references, page 1 of 5
Abstract
// Hanni Uusi-Kerttula 1 , James Davies 1 , Lynda Coughlan 2 , Sarah Hulin-Curtis 1 , Rachel Jones 3 , Louise Hanna 3 , John D. Chester 1, 3 , Alan L. Parker 1 1 Department of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK 2 Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK 3 Velindre Cancer Centre, Cardiff CF14 2TL, UK Correspondence to: Alan L. Parker, e-mail: parkeral@cardiff.ac.uk Keywords: adenovirus, re-targeting, neutralizing antibody, ovarian cancer, αvβ6 integrin Received: February 05, 2016      Accepted: March 28, 2016      Published: April 1, 2016 ABSTRACT Encouraging res...
Subjects
Medical Subject Headings: viruses
free text keywords: Research Paper, adenovirus, re-targeting, neutralizing antibody, ovarian cancer, αvβ6 integrin, R1, Oncology, Virology, biology.protein, biology, Immunology, Virotherapy, medicine.disease, medicine, Pseudotyping, Oncolytic virus, Transduction (genetics), business.industry, business, Cancer cell, Cancer research, Cancer
Related Organizations
67 references, page 1 of 5

Ovarian cancer statistics. Cancer Research UK. 2012

Coughlan, L, Alba, R, Parker, AL, Bradshaw, AC, McNeish, IA, Nicklin, SA, Baker, AH. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses. 2010; 2: 2290-2355 [OpenAIRE] [PubMed]

Xia, D, Henry, LJ, Gerard, RD, Deisenhofer, J. Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1. 7 å resolution. Structure. 1994; 2: 1259-1270 [PubMed]

Zubieta, C, Schoehn, G, Chroboczek, J, Cusack, S. The structure of the human adenovirus 2 penton. Mol Cell. 2005; 17: 121-135 [OpenAIRE] [PubMed]

Wickham, TJ, Mathias, P, Cheresh, DA, Nemerow, GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993; 73: 309-319 [OpenAIRE] [PubMed]

Nicol, CG, Graham, D, Miller, WH, White, SJ, Smith, TAG, Nicklin, SA, Stevenson, SC, Baker, AH. Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther. 2004; 10: 344-354 [PubMed]

Carlisle, RC, Di, Y, Cerny, AM, Sonnen, AFP, Sim, RB, Green, NK, Subr, V, Ulbrich, K, Gilbert, RJC, Fisher, KD, Finberg, RW, Seymour, LW. Human erythrocytes bind and inactivate type 5 adenovirus by presenting coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009; 113: 1909-1918 [OpenAIRE] [PubMed]

Seiradake, E, Henaff, D, Wodrich, H, Billet, O, Perreau, M, Hippert, C, Mennechet, F, Schoehn, G, Lortat-Jacob, H, Dreja, H, Ibanes, S, Kalatzis, V, Wang, JP, Finberg, RW, Cusack, S, Kremer, EJ. The cell adhesion molecule “CAR” And sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Path. 2009; 5: e1000277 [OpenAIRE]

Li, Y, Pong, RC, Bergelson, JM, Hall, MC, Sagalowsky, AI, Tseng, CP, Wang, Z, Hsieh, JT. Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res. 1999; 59: 325-330 [OpenAIRE] [PubMed]

Kim, M, Zinn, KR, Barnett, BG, Sumerel, LA, Krasnykh, V, Curiel, DT, Douglas, JT. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer. 2002; 38: 1917-1926 [OpenAIRE] [PubMed]

Mast, TC, Kierstead, L, Gupta, SB, Nikas, AA, Kallas, EG, Novitsky, V, Mbewe, B, Pitisuttithum, P, Schechter, M, Vardas, E, Wolfe, ND, Aste-Amezaga, M, Casimiro, DR, Coplan, P, Straus, WL, Shiver, JW. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high ad5 titers and implications for potential hiv vaccine trials. Vaccine. 2010; 28: 950-957 [PubMed]

Abbink, P, Lemckert, AAC, Ewald, BA, Lynch, DM, Denholtz, M, Smits, S, Holterman, L, Damen, I, Vogels, R, Thorner, AR, Brien, KL, Carville, A, Mansfield, KG, Goudsmit, J, Havenga, MJE, Barouch, DH. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007; 81: 4654-4663 [OpenAIRE] [PubMed]

Barouch, DH, Kik, SV, Weverling, GJ, Dilan, R, King, SL, Maxfield, LF, Clark, S, Ng'ang'a, D, Brandariz, KL, Abbink, P, Sinangil, F, de Bruyn, G, Gray, GE, Roux, S, Bekker, LG, Dilraj, A, Kibuuka, H, Robb, ML, Michael, NL, Anzala, O, Amornkul, PN, Gilmour, J, Hural, J, Buchbinder, SP, Seaman, MS, Dolin, R, Baden, LR, Carville, A, Mansfield, KG, Pau, MG, Goudsmit, J. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011; 29: 5203-5209 [OpenAIRE] [PubMed]

Kanerva, A, Zinn, KR, Chaudhuri, TR, Lam, JT, Suzuki, K, Uil, TG, Hakkarainen, T, Bauerschmitz, GJ, Wang, M, Liu, B, Cao, Z, Alvarez, RD, Curiel, DT, Hemminki, A. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther. 2003; 8: 449-458 [PubMed]

Morrison, J, Briggs, SS, Green, NK, Thoma, C, Fisher, KD, Kehoe, S, Seymour, LW. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum Gene Ther. 2009; 20: 239-251 [PubMed]

67 references, page 1 of 5
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2016

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies

Hanni Uusi-Kerttula; James Davies; Lynda Coughlan; Sarah Hulin-Curtis; Rachel Jones; Louise Hanna; John D. Chester; Alan L. Parker;